Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms

John D. Day, Joseph A. Digiuseppe, Charles Yeo, Myla Lai-Goldman, Steven M. Anderson, Steven N. Goodman, Scott E. Kern, Ralph H. Hruban

Research output: Contribution to journalArticle

Abstract

Although several morphological and molecular genetic studies have implicated various grades of pancreatic duct hyperplasia as precursor lesions to infiltrating pancreatic adenocarcinoma, the identity of preinvasive pancreatic neoplasms remains controversial. In the present study, the authors examined the expression of the epidermal growth factor receptor homologue, HER-2/neu (c-erbB-2), in pancreatic duct lesions adjacent to infiltrating pancreas cancers in a series of 19 cases of pancreatic duct adenocarcinoma. HER-2/neu expression was examined because it has been identified in a proportion of infiltrating pancreas cancers and because it may provide early neoplasms with a growth advantage over adjacent nonneoplastic epithelium. In normal pancreatic ducts anti ductules, HER-2/neu expression was absent in all but one case. By contrast, HER-2/neu was expressed in 82% (P = .008 vs normal) of ducts with fiat mucinous hyperplasia, 86% (P = .03 vs normal) of ducts with papillary mucinous hyperplasia without atypia, 92% (P = .001 vs normal) of ducts with atypical papillary mucinous hyperplasia, and all specimens with carcinoma in situ. HER-2/neu expression was observed in 69% (P = .002 vs normal) of the moderately differentiated infiltrating carcinomas and none of the poorly differentiated infiltrating carcinomas. These data establish HER-2/neu as a potential mediator of growth factor-related signal transduction in pancreatic duct lesions, and provide additional support for the hypothesis that lesions formerly regarded as various grades of hyperplasia instead may represent intraepithelial neoplasms with the potential for subsequent invasion and metastasis.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalHuman Pathology
Volume27
Issue number2
DOIs
StatePublished - 1996

Fingerprint

Pancreatic Ducts
Carcinoma in Situ
Pancreatic Neoplasms
Hyperplasia
Adenocarcinoma
Carcinoma
Epidermal Growth Factor Receptor
Molecular Biology
Signal Transduction
Intercellular Signaling Peptides and Proteins
Epithelium
Neoplasm Metastasis
Growth
Neoplasms

Keywords

  • c-erbB-2
  • HER-2/neu
  • pancreatic duct hyperplasia
  • pancreatic neoplasm

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. / Day, John D.; Digiuseppe, Joseph A.; Yeo, Charles; Lai-Goldman, Myla; Anderson, Steven M.; Goodman, Steven N.; Kern, Scott E.; Hruban, Ralph H.

In: Human Pathology, Vol. 27, No. 2, 1996, p. 119-124.

Research output: Contribution to journalArticle

Day, John D. ; Digiuseppe, Joseph A. ; Yeo, Charles ; Lai-Goldman, Myla ; Anderson, Steven M. ; Goodman, Steven N. ; Kern, Scott E. ; Hruban, Ralph H. / Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. In: Human Pathology. 1996 ; Vol. 27, No. 2. pp. 119-124.
@article{743d80b7df444fdb93272c09949d9b3d,
title = "Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms",
abstract = "Although several morphological and molecular genetic studies have implicated various grades of pancreatic duct hyperplasia as precursor lesions to infiltrating pancreatic adenocarcinoma, the identity of preinvasive pancreatic neoplasms remains controversial. In the present study, the authors examined the expression of the epidermal growth factor receptor homologue, HER-2/neu (c-erbB-2), in pancreatic duct lesions adjacent to infiltrating pancreas cancers in a series of 19 cases of pancreatic duct adenocarcinoma. HER-2/neu expression was examined because it has been identified in a proportion of infiltrating pancreas cancers and because it may provide early neoplasms with a growth advantage over adjacent nonneoplastic epithelium. In normal pancreatic ducts anti ductules, HER-2/neu expression was absent in all but one case. By contrast, HER-2/neu was expressed in 82{\%} (P = .008 vs normal) of ducts with fiat mucinous hyperplasia, 86{\%} (P = .03 vs normal) of ducts with papillary mucinous hyperplasia without atypia, 92{\%} (P = .001 vs normal) of ducts with atypical papillary mucinous hyperplasia, and all specimens with carcinoma in situ. HER-2/neu expression was observed in 69{\%} (P = .002 vs normal) of the moderately differentiated infiltrating carcinomas and none of the poorly differentiated infiltrating carcinomas. These data establish HER-2/neu as a potential mediator of growth factor-related signal transduction in pancreatic duct lesions, and provide additional support for the hypothesis that lesions formerly regarded as various grades of hyperplasia instead may represent intraepithelial neoplasms with the potential for subsequent invasion and metastasis.",
keywords = "c-erbB-2, HER-2/neu, pancreatic duct hyperplasia, pancreatic neoplasm",
author = "Day, {John D.} and Digiuseppe, {Joseph A.} and Charles Yeo and Myla Lai-Goldman and Anderson, {Steven M.} and Goodman, {Steven N.} and Kern, {Scott E.} and Hruban, {Ralph H.}",
year = "1996",
doi = "10.1016/S0046-8177(96)90364-0",
language = "English (US)",
volume = "27",
pages = "119--124",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms

AU - Day, John D.

AU - Digiuseppe, Joseph A.

AU - Yeo, Charles

AU - Lai-Goldman, Myla

AU - Anderson, Steven M.

AU - Goodman, Steven N.

AU - Kern, Scott E.

AU - Hruban, Ralph H.

PY - 1996

Y1 - 1996

N2 - Although several morphological and molecular genetic studies have implicated various grades of pancreatic duct hyperplasia as precursor lesions to infiltrating pancreatic adenocarcinoma, the identity of preinvasive pancreatic neoplasms remains controversial. In the present study, the authors examined the expression of the epidermal growth factor receptor homologue, HER-2/neu (c-erbB-2), in pancreatic duct lesions adjacent to infiltrating pancreas cancers in a series of 19 cases of pancreatic duct adenocarcinoma. HER-2/neu expression was examined because it has been identified in a proportion of infiltrating pancreas cancers and because it may provide early neoplasms with a growth advantage over adjacent nonneoplastic epithelium. In normal pancreatic ducts anti ductules, HER-2/neu expression was absent in all but one case. By contrast, HER-2/neu was expressed in 82% (P = .008 vs normal) of ducts with fiat mucinous hyperplasia, 86% (P = .03 vs normal) of ducts with papillary mucinous hyperplasia without atypia, 92% (P = .001 vs normal) of ducts with atypical papillary mucinous hyperplasia, and all specimens with carcinoma in situ. HER-2/neu expression was observed in 69% (P = .002 vs normal) of the moderately differentiated infiltrating carcinomas and none of the poorly differentiated infiltrating carcinomas. These data establish HER-2/neu as a potential mediator of growth factor-related signal transduction in pancreatic duct lesions, and provide additional support for the hypothesis that lesions formerly regarded as various grades of hyperplasia instead may represent intraepithelial neoplasms with the potential for subsequent invasion and metastasis.

AB - Although several morphological and molecular genetic studies have implicated various grades of pancreatic duct hyperplasia as precursor lesions to infiltrating pancreatic adenocarcinoma, the identity of preinvasive pancreatic neoplasms remains controversial. In the present study, the authors examined the expression of the epidermal growth factor receptor homologue, HER-2/neu (c-erbB-2), in pancreatic duct lesions adjacent to infiltrating pancreas cancers in a series of 19 cases of pancreatic duct adenocarcinoma. HER-2/neu expression was examined because it has been identified in a proportion of infiltrating pancreas cancers and because it may provide early neoplasms with a growth advantage over adjacent nonneoplastic epithelium. In normal pancreatic ducts anti ductules, HER-2/neu expression was absent in all but one case. By contrast, HER-2/neu was expressed in 82% (P = .008 vs normal) of ducts with fiat mucinous hyperplasia, 86% (P = .03 vs normal) of ducts with papillary mucinous hyperplasia without atypia, 92% (P = .001 vs normal) of ducts with atypical papillary mucinous hyperplasia, and all specimens with carcinoma in situ. HER-2/neu expression was observed in 69% (P = .002 vs normal) of the moderately differentiated infiltrating carcinomas and none of the poorly differentiated infiltrating carcinomas. These data establish HER-2/neu as a potential mediator of growth factor-related signal transduction in pancreatic duct lesions, and provide additional support for the hypothesis that lesions formerly regarded as various grades of hyperplasia instead may represent intraepithelial neoplasms with the potential for subsequent invasion and metastasis.

KW - c-erbB-2

KW - HER-2/neu

KW - pancreatic duct hyperplasia

KW - pancreatic neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0030030897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030030897&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(96)90364-0

DO - 10.1016/S0046-8177(96)90364-0

M3 - Article

C2 - 8617452

AN - SCOPUS:0030030897

VL - 27

SP - 119

EP - 124

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 2

ER -